Eupraxia Pharmaceuticals (NASDAQ:EPRX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) posted its quarterly earnings data on Tuesday. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03, Zacks reports.

Eupraxia Pharmaceuticals Stock Up 2.8%

Shares of EPRX stock traded up $0.21 during trading hours on Tuesday, reaching $7.63. 475,814 shares of the company’s stock were exchanged, compared to its average volume of 388,924. Eupraxia Pharmaceuticals has a fifty-two week low of $5.63 and a fifty-two week high of $9.32. The company has a market cap of $513.04 million, a price-to-earnings ratio of -7.48 and a beta of 1.04. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $7.56 and its 200-day moving average is $7.26.

Analyst Ratings Changes

A number of brokerages have commented on EPRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 15th. Royal Bank Of Canada began coverage on Eupraxia Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $14.00 target price for the company. Stifel Nicolaus set a $25.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Finally, Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.17.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.